Kalvista pharmaceuticals, inc. (KALV)
CashFlow / TTM
Jan'20Oct'19Jul'19Apr'19Jan'19Oct'18Jul'18Apr'18Jan'18Oct'17Jul'17Apr'17Jan'17Oct'16Sep'16Jul'16Jun'16Apr'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash Flows from Operating Activities
Net loss

-31,058

-25,723

-23,124

-20,816

-12,947

-14,225

-15,907

-15,805

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-21,008

-

-22,001

0

-24,606

-

-26,269

-24,846

-23,901

-22,905

-16,528

-13,359

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

504

473

449

378

307

254

198

180

140

119

72

40

63

-

69

0

102

-

136

133

115

99

75

54

0

0

0

Stock-based compensation expense

4,204

3,879

3,693

2,966

2,401

1,889

1,186

1,060

945

294

303

394

596

-

1,303

0

1,310

-

1,035

785

0

0

0

-

-

-

-

Realized (gain) from available for sale securities

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of right of use assets

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of preferred stock warrant liability and derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-520

0

0

0

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-95

-

-130

-

-180

-229

0

0

0

-

-

-

-

Stock based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of preferred stock warrant liability and derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Amortization of discount/premium on available for sale securities

0

0

0

-

-

-

-

-

-

-

-

-

-

-

90

-

105

-

80

780

0

0

0

-

-

-

0

Foreign currency exchange gain

284

387

-368

80

171

456

677

651

407

-366

-55

1,371

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

Impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Research and development tax credit receivable

5,879

4,768

7,862

4,883

4,282

3,551

2,807

4,256

1,680

1,347

855

600

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

Grants and other receivables

-

-

-

-

-

-

-

-319

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-309

677

1,349

1,979

2,015

627

730

746

598

1,577

493

81

604

-

-1,294

0

-804

-

10

532

1,408

1,431

930

561

0

0

0

Grants receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

0

-

-

-

-

-

-

-

-

Accounts payable

-81

-1,112

800

1,534

1,417

2,444

572

217

906

-981

173

-1,599

-2,229

-

-1,177

0

-1,711

-

-928

355

623

1,005

1,474

487

0

0

0

Accrued expenses

1,482

2,035

1,391

2,665

1,217

833

1,474

1,132

-39

-1,916

-2,748

-1,931

-1,806

-

141

0

29

-

-690

-298

-480

554

858

830

0

0

0

Lease obligations

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-11,792

-14,105

-15,778

-16,127

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-29

-

-29

-

-29

-29

0

0

0

-

-

-

-

Net cash used in operating activities

-42,709

-40,456

-41,428

-36,365

-31,809

7,267

8,794

10,558

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash Flows from Investing Activities
Acquisition of property and equipment

487

507

614

1,081

1,890

2,052

1,882

1,427

350

174

123

74

251

-

624

0

645

-

663

659

356

342

338

159

0

0

0

Deferred licensing revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by (used in) operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-26,165

-

-19,027

0

-22,717

-

-21,898

-20,863

-20,133

-18,051

-13,548

-11,253

0

0

0

Purchases of available for sale securities

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales and maturities of available for sale securities

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-7,321

-71,680

-70,387

-69,422

-56,459

-2,052

-1,882

-1,427

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash Flows from Financing Activities
Proceeds from issuance of common stock from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

155

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

33,888

-

-1,156

0

-1,177

-

-1,378

-1,374

-356

-342

-338

-159

0

0

0

Capital lease principal payments

107

159

211

209

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock from equity incentive plans

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock, net of offering expenses

11,521

11,521

94,332

87,910

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

11,738

11,749

94,395

87,943

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-543

-

-

-

768

1,988

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,000

0

0

0

-

-

-

-

Proceeds from loans payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,208

0

0

0

Net cash from financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

72,063

71,042

76,598

7,791

5,528

0

0

0

Effect of exchange rate changes on cash

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-17,963

-

-

-

21,614

20,105

25,180

19,611

16,328

9,186

6,466

-

-24,670

0

-28,562

-

45,274

49,826

50,553

58,205

-6,095

-5,884

0

0

0

Issuance of preferred stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

103

0

0

0

Capital leases

-

-

-

-

-

-

-

513

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

741

-

741

-

181

180

76

612

642

626

0

0

0

Transfer of long-term deposits to property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

0

-

-

-

-

-

-

-

-

Acquisition of property and equipment in accounts payable

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Accrual of deferred public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Derivative related to convertible promissory notes at issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Beneficial conversion feature for convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-